TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Michael Oestergaard
Research Fellow at Ionis Pharmaceuticals

Profile

Dr. Michael Østergaard is a Research Fellow at Ionis Pharmaceuticals with extensive knowledge of the properties and chemistry of oligonucleotides. He received his first oligonucleotide training at the Nucleic Acid Center at University of Southern Denmark and earned his Master in Chemistry in 2006. In 2010 he earned his Ph. D. at the University of Idaho exploring conformationally restricted nucleotides. Dr. Østergaard is a medicinal chemist at Ionis Pharmaceuticals conducting research to improve the properties of antisense oligonucleotides. Dr. Østergaard is a co-author on 45 peer-reviewed articles and inventor on 9 patents.

Michael Oestergaard's Network

Agenda Sessions

  • Gap Modifications Improve Therapeutic Index of Gapmer ASOs

    , 15:00
  • Targeted Delivery of Antisense Oligonucleotides to Extra-hepatic Tissues

    , 15:30
  • Targeted Delivery of Antisense Oligonucleotides to Extra-hepatic Tissues

    , 15:30